In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 7037-49-2, name is 3-(Piperidin-4-yl)propan-1-ol, introducing its new discovery. name: 3-(Piperidin-4-yl)propan-1-ol
N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR beta AGONISTS, COMPOSITIONS, AND THEIR USE
Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-beta receptor(LXRbeta) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer’s disease.
The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 7037-49-2 is helpful to your research. name: 3-(Piperidin-4-yl)propan-1-ol
Reference£º
Piperidine – Wikipedia,
Piperidine | C5H8195N – PubChem